Pfizer's sigvotatug vedotin fails to extend survival versus docetaxel
Pfizer just shared some tough news: its new lung cancer drug, sigvotatug vedotin, didn't help patients live longer in a big key trial.
The study focused on advanced cases with a tricky protein called integrin beta-6, found in most of these cancers and known for making things harder.
Sadly, the drug wasn't any better than the usual treatment, docetaxel.
Pfizer testing sigvotatug vedotin with Keytruda
This drug was part of Pfizer's massive $43 billion deal to buy Seagen Inc. hoping to boost its cancer research game.
After the trial results were released, Pfizer's stock slipped a bit.
Still, it is not giving up: Pfizer is already testing sigvotatug vedotin with Merck's Keytruda for newly diagnosed patients.
Chief Oncology Officer Jeff Legos says this setback is just one step in its journey, and earlier studies hint the drug might work better if used earlier or combined with other treatments.